- Investing Ideas
- /
- Argentinian Pharmaceuticals & Biotech Potentially Undervalued Companies
Argentinian Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Apr 22, 2024
Companies with a Value score of at least 3, ordered by Value score
16 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
GILD | US$17,755.50 | -2.2% | 78.7% | US$83.5b | US$22,578.90 | PE14.7x | E10.1% | 4.6% | ||
DJNJ3D | US$1,168.00 | -4.3% | 145.9% | US$356.4b | US$1,362.40 | PE18.6x | E5.1% | 3.4% | ||
BIIB | US$15,803.50 | -2.5% | 55.6% | US$28.2b | US$23,677.78 | PE24.3x | E18.2% | n/a | ||
AMGND | US$9.75 | 3.7% | 12.9% | US$145.8b | US$10.77 | PE21.7x | E8.8% | 3.3% | ||
BMY | US$17,371.50 | 0.05% | 59.2% | US$99.6b | US$19,865.59 | PE12.4x | E7.8% | 4.9% | ||
AMGN | US$9,610.00 | 1.0% | 152.2% | US$145.8b | US$10,612.20 | PE21.7x | E8.8% | 3.3% | ||
BIIBD | US$16.25 | -18.8% | n/a | US$28.2b | US$24.35 | PE24.3x | E18.2% | n/a | ||
GSKD | UK£10.30 | -7.6% | 11.1% | UK£67.0b | UK£12.60 | PE13.6x | E9.4% | 3.5% | ||
GSK | UK£10,758.00 | 0.2% | 151.4% | UK£67.0b | UK£13,161.51 | PE13.6x | E9.4% | 3.5% | ||
GILDD | US$17.60 | 3.8% | -21.3% | US$83.5b | US$22.38 | PE14.7x | E10.1% | 4.6% | ||
MRK | US$26,944.50 | 0.3% | 148.1% | US$321.5b | US$29,203.37 | PE880.9x | E25.9% | 2.4% | ||
JNJ | US$10,526.00 | 1.3% | 105.2% | US$359.3b | US$12,253.81 | PE18.7x | E5.1% | 3.3% | ||
MRKD | US$27.15 | 4.4% | 14.1% | US$321.5b | US$29.43 | PE880.9x | E25.9% | 2.4% | ||
JNJD | US$10.80 | 5.9% | -4.4% | US$359.3b | US$12.57 | PE18.7x | E5.1% | 3.3% | ||
NVSD | CHF24.25 | 0.8% | -4.9% | CHF187.3b | CHF27.38 | PE24x | E9.5% | 3.8% | ||
NVS | CHF25,399.50 | 1.2% | 109.5% | CHF191.3b | CHF28,117.66 | PE24.5x | E9.5% | 3.8% |
Page 1 of 1